Deregulation of Hh self-renewal pathway signaling, through GLI1 and GLI2 activation, has been linked to cancer stem cell generation and therapeutic resistance in MM18–20 and other hematopoietic malignancies21–23. This evidence concerns the gene GLI2 and cancer.